Champions Oncology, Inc. (CSBR)

Market Cap	66.61M
Revenue (ttm)	50.16M
Net Income (ttm)	-7.28M
Shares Out	13.59M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	22.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,432
Open	5.00
Previous Close	4.79
Day's Range	4.90 - 5.09
52-Week Range	4.50 - 7.13
Beta	0.49
Analysts	Buy
Price Target	7.50 (+50.0%)
Earnings Date	Jul 18, 2024

About CSBR

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 1986
• Employees: 230
• Stock Exchange: NASDAQ
• Ticker Symbol: CSBR

Financial Performance

In 2024, CSBR's revenue was $50.16 million, a decrease of -6.90% compared to the previous year's $53.87 million. Losses were -$7.28 million, 36.4% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CSBR stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 50.00% from the latest price.

Price Target

$7.5

(50.00% upside)

Analyst Consensus: Buy